Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis
Purpose: The treatment paradigm for mantle cell lymphoma (MCL), a B-cell malignancy, has shifted considerably during the past decades. This study aimed to evaluate time trends in overall survival (OS) and disease-specific mortality (DSM) of younger (age ≤ 65 years) patients with MCL from 1995 to 20...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.588314/full |
| _version_ | 1828759378224742400 |
|---|---|
| author | Hongyu Wu Hongyu Wu Hongyu Wu Jianwei Wang Jianwei Wang Jianwei Wang Xuanye Zhang Xuanye Zhang Xuanye Zhang Hang Yang Hang Yang Hang Yang Yu Wang Yu Wang Yu Wang Peng Sun Peng Sun Peng Sun Qingqing Cai Qingqing Cai Qingqing Cai Yi Xia Yi Xia Yi Xia Panpan Liu Panpan Liu Panpan Liu |
| author_facet | Hongyu Wu Hongyu Wu Hongyu Wu Jianwei Wang Jianwei Wang Jianwei Wang Xuanye Zhang Xuanye Zhang Xuanye Zhang Hang Yang Hang Yang Hang Yang Yu Wang Yu Wang Yu Wang Peng Sun Peng Sun Peng Sun Qingqing Cai Qingqing Cai Qingqing Cai Yi Xia Yi Xia Yi Xia Panpan Liu Panpan Liu Panpan Liu |
| author_sort | Hongyu Wu |
| collection | DOAJ |
| description | Purpose: The treatment paradigm for mantle cell lymphoma (MCL), a B-cell malignancy, has shifted considerably during the past decades. This study aimed to evaluate time trends in overall survival (OS) and disease-specific mortality (DSM) of younger (age ≤ 65 years) patients with MCL from 1995 to 2016.Methods: We used the Surveillance, Epidemiology, and End Results database. Year of diagnosis was divided into three eras: the chemotherapy-alone era (1995–2000), intensified-immunochemotherapy era (2001–2012), and targeted-therapy era (2013–2016). We used the Kaplan–Meier method, log-rank test, and subdistribution proportional hazard regression in the analysis.Results: A total 4,892 patients were identified. Median OS increased from 67 months in the chemotherapy-alone era to 107 months in the intensified-immunochemotherapy era (P < 0.001). The DSM rate decreased significantly from 1995 to 2016 (P < 0.001); the adjusted hazard ratios of MCL-specific death were 0.589 (P < 0.001) for the intensified-immunochemotherapy era and 0.459 (P < 0.001) for targeted-therapy era, as compared with the chemotherapy-alone era. Patients with advanced-stage MCL exhibited lowering risk of death across the three eras (P < 0.001).Conclusions: During 1995–2016, survival in younger patients with MCL increased significantly, especially those with advanced-stage disease, potentially reflecting the impact of advancement in treatment modalities on MCL outcome. |
| first_indexed | 2024-12-11T00:57:16Z |
| format | Article |
| id | doaj.art-a3b3c69835e44d04b84ace50322a01ba |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T00:57:16Z |
| publishDate | 2020-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a3b3c69835e44d04b84ace50322a01ba2022-12-22T01:26:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-10-011010.3389/fonc.2020.588314588314Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based AnalysisHongyu Wu0Hongyu Wu1Hongyu Wu2Jianwei Wang3Jianwei Wang4Jianwei Wang5Xuanye Zhang6Xuanye Zhang7Xuanye Zhang8Hang Yang9Hang Yang10Hang Yang11Yu Wang12Yu Wang13Yu Wang14Peng Sun15Peng Sun16Peng Sun17Qingqing Cai18Qingqing Cai19Qingqing Cai20Yi Xia21Yi Xia22Yi Xia23Panpan Liu24Panpan Liu25Panpan Liu26Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaPurpose: The treatment paradigm for mantle cell lymphoma (MCL), a B-cell malignancy, has shifted considerably during the past decades. This study aimed to evaluate time trends in overall survival (OS) and disease-specific mortality (DSM) of younger (age ≤ 65 years) patients with MCL from 1995 to 2016.Methods: We used the Surveillance, Epidemiology, and End Results database. Year of diagnosis was divided into three eras: the chemotherapy-alone era (1995–2000), intensified-immunochemotherapy era (2001–2012), and targeted-therapy era (2013–2016). We used the Kaplan–Meier method, log-rank test, and subdistribution proportional hazard regression in the analysis.Results: A total 4,892 patients were identified. Median OS increased from 67 months in the chemotherapy-alone era to 107 months in the intensified-immunochemotherapy era (P < 0.001). The DSM rate decreased significantly from 1995 to 2016 (P < 0.001); the adjusted hazard ratios of MCL-specific death were 0.589 (P < 0.001) for the intensified-immunochemotherapy era and 0.459 (P < 0.001) for targeted-therapy era, as compared with the chemotherapy-alone era. Patients with advanced-stage MCL exhibited lowering risk of death across the three eras (P < 0.001).Conclusions: During 1995–2016, survival in younger patients with MCL increased significantly, especially those with advanced-stage disease, potentially reflecting the impact of advancement in treatment modalities on MCL outcome.https://www.frontiersin.org/articles/10.3389/fonc.2020.588314/fullmantle cell lymphomanon-Hodgkin lymphomasurvivalSEER programimmunotherapy |
| spellingShingle | Hongyu Wu Hongyu Wu Hongyu Wu Jianwei Wang Jianwei Wang Jianwei Wang Xuanye Zhang Xuanye Zhang Xuanye Zhang Hang Yang Hang Yang Hang Yang Yu Wang Yu Wang Yu Wang Peng Sun Peng Sun Peng Sun Qingqing Cai Qingqing Cai Qingqing Cai Yi Xia Yi Xia Yi Xia Panpan Liu Panpan Liu Panpan Liu Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis Frontiers in Oncology mantle cell lymphoma non-Hodgkin lymphoma survival SEER program immunotherapy |
| title | Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis |
| title_full | Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis |
| title_fullStr | Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis |
| title_full_unstemmed | Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis |
| title_short | Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis |
| title_sort | survival trends in patients under age 65 years with mantle cell lymphoma 1995 2016 a seer based analysis |
| topic | mantle cell lymphoma non-Hodgkin lymphoma survival SEER program immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2020.588314/full |
| work_keys_str_mv | AT hongyuwu survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT hongyuwu survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT hongyuwu survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT jianweiwang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT jianweiwang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT jianweiwang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT xuanyezhang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT xuanyezhang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT xuanyezhang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT hangyang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT hangyang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT hangyang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT yuwang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT yuwang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT yuwang survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT pengsun survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT pengsun survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT pengsun survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT qingqingcai survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT qingqingcai survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT qingqingcai survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT yixia survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT yixia survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT yixia survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT panpanliu survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT panpanliu survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis AT panpanliu survivaltrendsinpatientsunderage65yearswithmantlecelllymphoma19952016aseerbasedanalysis |